STAT3 and hepatocellular carcinoma: Following earlier studies suggesting that ASC‐J9® may alter activated p‐STAT3 signals to suppress prostate cancer metastasis, here the authors found that combining Sorafenib with ASC‐J9® may synergistically suppress HCC progression.